AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Cannot have received: antitumor therapy

Exception: therapy with 5 times the half-life being shorter than 21 days (enrollment may be allowed with washout from prior therapy of < 21 days)

Antitumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or investigational agent) within 21 days of first dose of trial treatment, unless anti-tumor therapy is a therapy with 5 times the half-life being shorter than 21 days (in this case, enrollment may be allowed with washout from prior therapy of < 21 days)

Cannot have received: radiation therapy

Exception: local or focal radiotherapy with palliative intent within 14 days of the first dose

Radiation therapy within 28 days of the first dose of trial treatment (or local or focal radiotherapy with palliative intent within 14 days of the first dose)